Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #95997 on Biotech Values
Imclonian
05/19/10 2:06 AM
#96005 RE: onco_investor #95997
Since 2000, when Reolysin first entered the clinic, Oncolytics has enrolled some 330 patients in multiple Phase 1 and 2 studies. “When we lump all indications together, you see this pattern, where people have a three-in-four chance of stabilizing or having a tumour regress fairly significantly. And an even higher percentage in metastatic lesions,” he adds.